Researcher
Bart Keymeulen
- Research Expertise:
Full professor of Medicine - Vrije Universiteit Brussel
Head Diabetes Clinic & Clinical Trial Center - UZ Brussel
Head Research Cluster Diabetes - Vrije Universiteit Brussel
Head Diabetes Biobank associated with Belgian Diabetes Registry
- Keywords:Medicine
- Users of research expertise:
Full professor of Medicine - Vrije Universiteit Brussel
Head Diabetes Clinic & Clinical Trial Center - UZ Brussel
Head Research Cluster Diabetes - Vrije Universiteit Brussel
Head Diabetes Biobank associated with Belgian Diabetes Registry
Affiliations
- Diabetes Pathology & Therapy (Research group)
Responsible
From2 Feb 2011 → Today - Diabetes Clinic (Department)
Member
From1 Jan 2008 → Today - Clinical sciences (Department)
Member
From1 Oct 2023 → Today - Pathology/molecular and cellular medicine (Department)
Member
From1 Oct 2019 → Today - Pathology/molecular and cellular medicine (Department)
Member
From8 Apr 2019 → 30 Sep 2023 - Pathology/molecular and cellular medicine (Department)
Responsible
From1 Jan 2014 → 20 Oct 2022 - Pathology/molecular and cellular medicine (Department)
Member
From1 Jan 2014 → 30 Sep 2016 - Internal Medicine Specializations (Department)
Member
From1 Apr 1997 → 31 Dec 2013 - Pathologic Biochemistry and Physiology (Department)
Member
From1 Oct 1989 → 31 Dec 2013
Projects
1 - 7 of 7
- Biologic Platform for Early Detection, Prevention and Treatment of Type 1 DiabetesFrom1 Mar 2024 → TodayFunding: BOF - projects
- Hilde Bruers prijs 2022From12 May 2022 → TodayFunding: Universities as sponsor
- Predicting impending beta cell loss and dysglycemia in asymptomatic type 1 diabetes - Validation of minimally invasive markers against the hyperglycemic clamp test.From1 Nov 2021 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: Platform for Clinical Trial Network to Prevent and Cure Type 1 DiabetesFrom1 Mar 2019 → 29 Feb 2024Funding: BOF - projects
- Beta Cell Generation by Stem Cell-Derived Implants in DiabetesFrom1 Dec 2015 → 31 Aug 2022Funding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- SRP (Groeiers): Biomarkers for staging diabetes and guiding its prevention and treatmentFrom1 Mar 2014 → 28 Feb 2019Funding: BOF - Concerted Research Project from 1994
- BetaCellTherapy : Beta Cell Therapy in Diabetes.From1 Jan 2010 → 30 Jun 2015Funding: Health
Publications
1 - 10 of 89
- Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium(2024)
Authors: Margaretha M Visser, Astrid Van Muylder, Sara Charleer, John J Isitt, Stéphane Roze, Christophe De Block, Toon Maes, Gerd Vanhaverbeke, Frank Nobels, Bart Keymeulen, et al.
Pages: 650-662 - Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes(2023)
Authors: Aster K Desouter, Bart Keymeulen, Simke Demeester, Pieter De Pauw, Annelien Van Dalem, Bruno Lapauw, Christophe De Block, Pieter Gillard, Danny Pipeleers, Frans K Gorus
- Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes(2023)
Authors: Mikaël Chetboun, Elodie Drumez, Cassandra Ballou, Mehdi Maanaoui, Elizabeth Payne, Franca Barton, Julie Kerr-Conte, Marie-Christine Vantyghem, Lorenzo Piemonti, Michael R Rickels, et al.
Pages: 391-401 - Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes(2023)
Authors: Valeria Sordi, Paolo Monti, Vito Lampasona, Raffaella Melzi, Silvia Pellegrini, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, et al.
- First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes(2023)
Authors: Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie, Mohammad Alhadj Ali, Colin Dayan, Bart Keymeulen, Katharine R Owen, Martin Kindermans, Frédéric Parmentier, Vincent Carlier, et al.
- CTLA4, SH2B3 and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of type 1 diabetes patients(2023)
Authors: Julie Vandewalle, Aster K Desouter, Bart J Van der Auwera, Sylvie Tenoutasse, Pieter Gillard, Christophe De Block, Bart Keymeulen, Frans K Gorus, Mark Van de Casteele
Pages: 224-232 - Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes(2023)
Authors: Margaretha M Visser, Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, Nele Myngheer, et al.
Pages: 96-108 - Histopathology of human islet cell implants(2023)
Authors: Freya Van Hulle, Bart Keymeulen, Danny Pipeleers
Number of pages: 135 - Comparison of Omentum and Subcutis as Implant Sites for Device-Encapsulated Human iPSC-Derived Pancreatic Endoderm in Nude Rats(2023)
Authors: Jolien R Nijns, Ines De Mesmaeker, Krista G Suenens, Geert Stangé, Kaat De Groot, Maria Marques de Lima, Marine R C Kraus, Bart Keymeulen, Wim Waelput, Daniel Jacobs-Tulleneers-Thevissen, et al.
- Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes(2022)
Authors: Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, Luisa Daffonchio, et al.
Pages: 1840-1849